Department of Medical Oncology, Cancer Center, Sun Yat-sen University, 651 Dong Feng RD East, Guangzhou 510060, PR China.
Br J Cancer. 2013 Feb 5;108(2):380-6. doi: 10.1038/bjc.2012.566. Epub 2013 Jan 8.
Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTL) is an aggressive disease with poor prognosis, requiring risk stratification. However, the prognosis of ENKTL is not fully defined and needs supplementation. We hypothesised that fasting blood glucose (FBG) may be a new prognostic factor for ENKTL.
We retrospectively analysed 130 patients newly diagnosed with ENKTL.
Both univariate analysis and multivariate analysis revealed that FBG >100 mg dl(-1) was associated with a poor outcome. Patients with FBG >100 mg dl(-1) at diagnosis had more adverse clinical features, achieved lower complete remission rates (P=0.003) and had worse overall survival (P<0.001) and progression-free survival (P<0.001) compared with low-FBG patients. Measurement of FBG was helpful in differentiating between low-risk patients using the International Prognostic Index (IPI) and Prognosis Index for peripheral T-cell lymphoma (PIT) scoring and patients in a different category using the Korean Prognostic Index (KPI) scores with different survival outcomes (P<0.05).
Our data suggest that measuring FBG levels at diagnosis is a novel, independent predictor of prognosis in ENKTL and helps to distinguish low-risk patients with poor survival, and this holds true in patients considered low-risk by IPI, PIT and KPI.
结外自然杀伤（NK）/T 细胞淋巴瘤，鼻型（ENKTL）是一种侵袭性疾病，预后不良，需要进行风险分层。然而，ENKTL 的预后并不完全明确，需要补充。我们假设空腹血糖（FBG）可能是 ENKTL 的一个新的预后因素。
我们回顾性分析了 130 例新诊断为 ENKTL 的患者。
单因素分析和多因素分析均显示，FBG＞100mg/dl 与不良预后相关。诊断时 FBG＞100mg/dl 的患者具有更多不良临床特征，完全缓解率较低（P=0.003），总生存（P＜0.001）和无进展生存（P＜0.001）更差。与低 FBG 患者相比，FBG 测量有助于区分国际预后指数（IPI）和外周 T 细胞淋巴瘤预后指数（PIT）评分中的低危患者以及不同 KPI 评分的不同生存结局的患者（P＜0.05）。
我们的数据表明，在 ENKTL 中，诊断时测量 FBG 水平是一种新的独立预后预测因子，有助于区分生存较差的低危患者，这在 IPI、PIT 和 KPI 评分中被认为是低危的患者中也是如此。
